The goal of this program is to improve management of cancerrelated thrombosis and aggressive lymphoma. After hearing and assimilating this program, the clinician will be better able to: 1. Evaluate the use of biomarkers in predicting risk for thromboembolism in patients with cancer. 2. Compare the effectiveness and safety of direct oral anticoagulants in the management of cancer-associated thrombosis. 3. Analyze the efficacy of newer regimens in the frontline therapy of diffuse large B-cell lymphoma (DLBCL). 4. Evaluate the efficacy of second-line therapies for relapsed/ refractory DLBCL. 5. Compare real-world outcomes of treatment of aggressive lymphoma with data from clinical trials.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2023-04-27 05:00:00
- End Date: 2023-04-27 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology